The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue

被引:88
|
作者
Mutch, Elaine [1 ]
Nave, Ruediger
McCracken, Nigel
Zech, Karl
Williams, Faith M.
机构
[1] Univ Newcastle, Toxicol Unit, Newcastle Upon Tyne, Tyne & Wear, England
[2] ALTANA Pharma AG, Constance, Germany
关键词
ciclesonide; carboxylesterase; esterases; liver; lung; metabolism;
D O I
10.1016/j.bcp.2007.01.031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ciclesonide (CIC) is an inhaled glucocorticosteroid. This study aimed to identify esterases involved in the metabolism of CIC to the active metabolite desisobutyryl-ciclesonide (des-CIC), and to measure hydrolysis rates in human liver, lung and plasma and normal human bronchial epithelial (NHBE) cells in vitro. Ciclesonide (5 mu M and 500 mu M) was incubated with microsomal or cytosolic fractions from liver, lung and plasma (n = 4 for each) and des-CIC formation was determined by reverse-phase high-performance liquid chromatography with U.V. detection. The roles of carboxylesterase, cholinesterase and A-esterase in CIC hydrolysis were determined using a range of inhibitors. Inhibitor concentrations for liver and NHBE cells were 100 mu M and 5 mu M, respectively. Liver tissue had a higher activity for 500 mu M CIC hydrolysis (microsomes: 25.4; cytosol: 62.9 nmol/g tissue/min) than peripheral lung (microsomes: 0.089; cytosol: 0.915 nmol/g tissue/min) or plasma (0.001 nmol/mL plasma/ min), corresponding with high levels of carboxylesterase and cholinesterase in the liver compared with the lung. CIC (5 mu M) was rapidly hydrolyzed by NHBE cells (similar to 30% conversion at 4 h), with almost complete conversion by 24 h. In liver and NHBE cells, major involvement of cytosolic carboxylesterases, with some contribution by cholinesterases, was indicated. The highest level of conversion was found in the liver, the site of inactivation of des-CIC through rapid oxidation by cytochrome P450. Carboxylesterases in bronchial epithelial cells probably contribute significantly to the conversion to des-CIC in the target organ, whereas low systemic levels of des-CIC are a result of the high metabolic clearance by the liver following CIC inhalation. (c) Inc2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1657 / 1664
页数:8
相关论文
共 50 条
  • [1] Modulation of human lung fibroblast functions by ciclesonide: Evidence for its conversion into the active metabolite desisobutyryl-ciclesonide
    Boero, Silvia
    Sabatini, Federica
    Silvestri, Michela
    Petecchia, Loredana
    Nachira, Antonio
    Pezzolo, Annalisa
    Scarso, Lucia
    Rossi, Giovanni A.
    IMMUNOLOGY LETTERS, 2007, 112 (01) : 39 - 46
  • [2] Reversibility of desisobutyryl-ciclesonide conversion to fatty acid conjugates
    Wingertzahn, M
    Nonaka, T
    Mochizuki, T
    Sato, H
    Kondo, S
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S167 - S167
  • [3] Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar
    Nave, F
    Gunawardena, KA
    Zech, K
    Bethke, TD
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2006, 44 (01) : 1 - 7
  • [4] Physiologic and structural characterization of desisobutyryl-ciclesonide, a selective glucocorticoid receptor modulator in newborn rats
    Jaumotte, Juliann D.
    El Khoury, Nathalie
    Min, Charles K.
    Wang, Jiefei
    Madigan, Caroline
    Jano, Antalya
    Kobylski, Robin J. Russo
    Solt, Laura A.
    Dhavan, Rutu S.
    Short, Kelly L.
    Lei, Tianhua
    Chandran, Uma
    Cole, Timothy J.
    Monaghan-Nichols, Ann Paula
    Sampath, Venkatesh
    Houtman, Rene
    Nettles, Kendall W.
    Defranco, Donald B.
    PNAS NEXUS, 2025, 4 (01):
  • [5] An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination of Ciclesonide and Active Metabolite Desisobutyryl-Ciclesonide in Human Serum and Its Application to a Clinical Study
    Chen, Yu-Luan
    Wang, Weimin
    Wetie, Armand Gatien Ngounou
    Shi, Lei
    Eddy, John
    Lin, Zhong-Ping John
    Sunkaraneni, Soujanya
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2020, 5 (01): : 41 - 53
  • [6] Simultaneous determination of ciclesonide and its active metabolite desisobutyryl-ciclesonide in human plasma by LC-APCI-MS/MS: Application to pharmacokinetic study in healthy Chinese volunteers
    Su, Meng-xiang
    Song, Min
    Zhuang, Ying
    Wang, Yong-qing
    Hang, Tai-jun
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 55 (01) : 230 - 235
  • [7] Effect of coadministered ketoconazole, a strong cytochrome p450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide
    Boehmer, Gabriele M.
    Drollmann, Anton
    Gleiter, Christoph H.
    Nave, Ruediger
    CLINICAL PHARMACOKINETICS, 2008, 47 (05) : 343 - 349
  • [8] Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide
    Böhmer G.M.
    Drollmann A.
    Gleiter C.H.
    Nave R.
    Clinical Pharmacokinetics, 2008, 47 (5) : 343 - 349
  • [9] LC-HRMS/MS study of the prodrug ciclesonide and its active metabolite desisobutyryl-ciclesonide in plasma after an inhalative administration to horses for doping control purposes
    Trevisiol, Stephane
    Moulard, Yves
    Kaabia, Zied
    Delcourt, Vivian
    Loup, Benoit
    Garcia, Patrice
    Boyer, Sophie
    Dauriac, Karine
    Groseille, Guillaume
    Rouger, Sebastien
    Narbe, Ruediger
    Popot, Marie-Agnes
    Bailly-Chouriberry, Ludovic
    DRUG TESTING AND ANALYSIS, 2022, 14 (02) : 252 - 261
  • [10] Esterases involved in the metabolism of ciclesonide (CIC) in human nasal epithelial cells (HNEC)
    Wingertzahn, MA
    Sato, H
    Nave, R
    Nonaka, T
    Mochizuki, T
    Takahama, S
    Kondo, S
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S167 - S167